Our top pick for
Repro Med Systems, Inc is a medical instruments & supplies business based in the US. Repro Med Systems shares (KRMD) are listed on the NASDAQ and all prices are listed in US Dollars. Repro Med Systems employs 71 staff and has a trailing 12-month revenue of around USD$26.3 million.
|52-week range||USD$3.6 - USD$12.84|
|50-day moving average||USD$5.0564|
|200-day moving average||USD$7.5341|
|Wall St. target price||USD$11.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.0177|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Repro Med Systems stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Repro Med Systems's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Repro Med Systems's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 398x. In other words, Repro Med Systems shares trade at around 398x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Repro Med Systems's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$3.6 million.
The EBITDA is a measure of a Repro Med Systems's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$26.3 million|
|Operating margin TTM||12.16%|
|Gross profit TTM||USD$14.9 million|
|Return on assets TTM||6.77%|
|Return on equity TTM||-1.8%|
|Market capitalisation||USD$267.6 million|
TTM: trailing 12 months
There are currently 953,418 Repro Med Systems shares held short by investors – that's known as Repro Med Systems's "short interest". This figure is 3.3% up from 923,217 last month.
There are a few different ways that this level of interest in shorting Repro Med Systems shares can be evaluated.
Repro Med Systems's "short interest ratio" (SIR) is the quantity of Repro Med Systems shares currently shorted divided by the average quantity of Repro Med Systems shares traded daily (recently around 570908.98203593). Repro Med Systems's SIR currently stands at 1.67. In other words for every 100,000 Repro Med Systems shares traded daily on the market, roughly 1670 shares are currently held short.
However Repro Med Systems's short interest can also be evaluated against the total number of Repro Med Systems shares, or, against the total number of tradable Repro Med Systems shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Repro Med Systems's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Repro Med Systems shares in existence, roughly 20 shares are currently held short) or 0.0492% of the tradable shares (for every 100,000 tradable Repro Med Systems shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Repro Med Systems.
Find out more about how you can short Repro Med Systems stock.
We're not expecting Repro Med Systems to pay a dividend over the next 12 months.
Over the last 12 months, Repro Med Systems's shares have ranged in value from as little as $3.6 up to $12.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Repro Med Systems's is 0.1617. This would suggest that Repro Med Systems's shares are less volatile than average (for this exchange).
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.
Steps to owning and managing DRIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing CYBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHCI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CKX, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTHR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CNBKA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CATM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRME, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.